Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results

Go back to Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results

Sagent Pharmaceuticals (SGNT) PT Trimmed at Piper Jaffray, But 'Overweight' Maintained on Pipeline

May 4, 2016 8:50 AM EDT

Piper Jaffray analyst David Amsellem lowered estimates and his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $22.00 (from $23.00) but maintained an Overweight rating following Q1 results. While the top lined was pressured, clarity on a deep pipeline is emerging, the analyst said.

Amsellem commented, "Sagent reported 1Q16 EPS of ($0.15) on... More

RBC Capital Cuts Price Target on Sagent Pharmaceuticals (SGNT) Following Weak Cold and Flu Season

May 4, 2016 6:47 AM EDT

RBC Capital maintained an Outperform rating on Sagent Pharmaceuticals (NASDAQ: SGNT), and cut the price target to $20.00 (from $28.00), following the company's 1Q earnings report. Weakness in SGNT's anti-infective business is due in part to a weak cold and flu season. This trend will... More

Sagent Pharmaceuticals (SGNT) Misses Q1 EPS by 16c

May 3, 2016 7:34 AM EDT

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q1 EPS of ($0.15), $0.16 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $67.3 million versus the consensus estimate of $74.3 million.

Sagents business plan for fiscal 2016 currently anticipates:

Net... More